Interviews
03 Jun 2020 - Cyclopharm (ASX:CYC) Managing Director and CEO James McBrayer provides an update on US FDA progress with Technegas, approval in Russia and potential use of Technegas in the diagnosis and management of COVID-19.
01 Jun 2020 - NetLinkz Limited (ASX:NET) Executive Chairman & CEO James Tsiolis provides an update on the company's suite of networking solutions, the market opportunity and progress with partners.
01 Jun 2020 - OncoSil Medical Limited (ASX:OSL) Managing Director and CEO Daniel Kenny talks about the significance of the company's CE Marking approval for its lead product OncoSil, which helps treat pancreatic, liver and biliary duct cancer.
27 May 2020 - Hazer Group Limited (ASX:HZR) Managing Director and CEO Geoff Ward talks about the Hazer process for low emissions hydrogen gas and high purity graphite production from biogas, CAPEX approval to proceed with the company's commercial demonstration plant and offtake discussions.
26 May 2020 - LBT Innovations Limited (ASX:LBT) Managing Director and CEO Brent Barnes talks about progress with the company's microbiology culture plate reading device APAS Independence, which uses artificial intelligence to read and interpret plates, additional analysis module development, sales pipeline and strategy.
22 May 2020 - Novonix Limited (ASX:NVX) Managing Director Philip St Baker talks about the company's breakthrough dry particle microgranulation (DPMG) method for reducing waste in the manufacture of anode and cathode materials for lithium-ion batteries, restarting of operations in North America and outlook for 2H20.
13 May 2020 - Elixinol Global (ASX:EXL) CEO, Oliver Horn talks about its strategy to create a global nutraceuticals brand, with a focus on higher margin, consumer branded products, new management team, capital raising and FY 20 outlook.
06 May 2020 - Acorn Capital Investment Fund Ltd. (ASX: ACQ) Head of Research and Portfolio Manager for the Consumer Discretionary, Consumer Staples and Information Technology sectors, Robert Bruce talks about the listed investment company, the fund's composition and outlook for the next 6 months and longer term.
01 May 2020 - Acorn Capital, Head of Portfolio Implementation and Portfolio manager (Healthcare and Biotechnology sectors) Paul Palumbo looks the microcap sector and the recent market sell off and discusses the outlook for next 6 months and longer term.
28 Apr 2020 - BrainChip Holdings (ASX:BRN BrainChip Holdings (ASX:BRN) CEO Lou DiNardo talks about its Akida integrated circuit, its advantages in event-based convolutional (e-conv) networks, applications and its move to wafer production and first engineering samples by Q3 2020.
27 Apr 2020 - Aus Tin Mining (ASX:ANW) CEO, Peter Williams talks farm-in agreement for exploration licences prospective for copper and gold in the Lachlan Fold Belt and proposal to divest its Granville Tin Mine.
27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.
24 Apr 2020 - Telix Pharmaceuticals (ASX:TLX), Chief Business Officer, David Cade talks about its prostate cancer imaging product, diagnostic and therapeutic products, partners and key priorities for 2020.
06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embolism in chronic chronic obstructive pulmonary ( COPD ) and asthma.
26 Mar 2020 - Lithium Consolidated Mineral Exploration Limited (ASX:LI3) Managing Director Andrew Haythorpe provides an update on the company's new WA projects prospective for gold, nickel and base metals, board changes and plans to improve the company's prospects.
31 Mar 2020 - BluGlass Limited (ASX:BLG) Managing Director and CEO,Giles Bourne, talks about the company's 1:1 non-renounceable rights issue, the need to fund its technology through to commercialisation, independent validation of its RPCVD technology and its response to COVID-19.
31 Mar 2020 - Cynata Therapeutics Limited (ASX:CYP) Managing Director, Dr Ross MacDonald, talks 1H20 results, upcoming Phase 2 clinical trials, licensing and strategy to build the company's Cymerus cell therapy platform.
30 Mar 2020 - XTEK Limited (ASX:XTE) Managing Director Philippe Odouard talks 1H20 results, the company's front-line products for the Australian Defence Force and police forces, US strategy and outlook.
26 Mar 2020 - Cashwerkz Limited (ASX:CWZ) Executive Chairman John Nantes talks about the company's 1H20 results, new partners to the platform, outlook for the second half and impact of COVID-19.
18 Mar 2020 - First Graphene Limited (ASX:FGR) Executive Director and CFO, Peter Youd, talks about the company's 1H20 results, progress with key customer trials and work at the Graphene Engineering & Innovation Centre (GEIC) in Manchester, UK.
13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi's blockbuster insomnia drug Ambien and focus for 2020.
11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
10 Mar 2020 - Prospect Resources Limited (ASX:PSC) Managing Director, Sam Hosack, provides an update on the company's key lithium petalite project in Zimbabwe.
10 Mar 2020 - Opthea Limited (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin talks about results from the company's lead drug candidate OPT-302, and new funding for further clinical development for wet AMD (age-related macular degeneration) and DME (diabetic macular degeneration).
09 Mar 2020 - Lithium Power International Limited (ASX:LPI) Managing Director and CEO Cristobal Garcia-Huidobro and Executive Director and CFO Andrew Phillips discuss the Environmental Approval for the company's Maricunga lithium brine project in Northern Chile, what this means for the project, and what's planned.
03 Mar 2020 - Catapult Limited (ASX:CAT) CEO, Will Lopes discusses 1H20 results and outlook.
02 Mar 2020 - Integrated Payment Technologies Limited (ASX:IP1) CEO, Dean Martin, discusses 1H20 results, customers numbers and take up for the company's ClickSuper and PayVu systems and integration with accounting platforms.
28 Feb 2020 - Washington H. Soul Pattinson and Company Limited (ASX:SOL) Managing Director, Todd Barlow provides a portfolio update and talks about the approach to investment that has enabled the company to outperform over decades.
27 Feb 2020 - NetLinkz Limited (ASX:NET) Executive Chairman and CEO, James Tsiolis talks about the significance of the company's agreement to provides its Virtual Secure Network to a World Bank-sponsored initiative to improve water sanitation services in selected areas of the Deyang Municipality of Sichuan Province.
27 Feb 2020 - Ingenia Communities Group Limited (ASX:INA) CFO, Scott Noble, discusses 1H20 results, the company's portfolio and the demand for seniors accommodation.
26 Feb 2020 - Renergen Limited (ASX:RLT) Managing Director and CEO, Stefano Marani provides an update on recent drilling results at the company's Virginia Gas Project in South Africa, what's planned for this year and the potential to bring forward a second production well.
25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
19 Feb 2020 - BluGlass Limited (ASX:BLG) Managing Director, Giles Bourne talks about the opportunities that laser diodes represent for the company, following the Photonics West Conference.
13 Feb 2020 - Centuria Capital Group (ASX:CNI) Joint CEO, John McBain talks 1H20 results & outlook, including the contribution from recent acquisitions as group AUM now exceeds $7.3B.
12 Feb 2020 - Mayur Resources Limited (ASX:MRL) Managing Director, Paul Mulder provides an update on the company's PNG projects, which span industrial minerals, power generation, coal, copper and gold.
05 Feb 2020 - Aus Tin Mining Limited (ASX:ANW) CEO, Peter Williams, talks about proposed drilling at the company's Taronga tin project and the potential for an upside in tin grades.
05 Feb 2020 - Centuria Industrial REIT (ASX:CIP) Fund Manager, Jesse Curtis talks 1H20 results, portfolio metrics and trends.
05 Feb 2020 - Centuria Metropolitan REIT (ASX:CMA) Fund Manager, Grant Nichols talks 1H20 results, portfolio metrics and guidance.
03 Feb 2020 - Embark Ventures Managing Partner Michael Curtis provides an update on talks about the company's role as investment manager for MMJ Group Holdings (ASX:MMJ), the Canadian cannabis market and what's planned for the portfolio.
03 Feb 2020 - ClearVue Technologies Limited (ASX:CPV) Executive Chairman, Victor Rosenberg, talks about certification of its solar PV Integrated Glass Unit (IGU) what the testing demonstrated and how this clears the way for sale into the US, Europe and other global territories.
31 Jan 2020 - Los Cerros Limited (ASX:LCL) Managing Director, Jason Stirbinskis, talks about the company's gold projects in Colombia, the potential for high grade porphyry deposits and plans to advance drilling at its Chuscal target.
10 Jan 2020 - Novatti Group Limited (ASX:NOV) CEO, Peter Cook, discusses funding for the Novatti's banking subsidiary, its banking licences and its core customer acquisition proposition.
09 Jan 2020 - IVE Group Limited (ASX:IGL) Executive Chairman, Geoff Selig, discusses the company's recent acquisition of Salmat Marketing Solutions and Reach Media New Zealand and its recent move to trading under the one IVE brand.
08 Jan 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker, talks about the company's plans to develop Anagrelide, for the treatment of cancer, and to commercialise its lead product ZolpiMist worldwide.
23 Dec 2019 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO, James McBrayer talks about the company's joint venture to expand Positron Emission Tomography (PET) diagnostics business opportunities for NSW and Australia.
19 Dec 2019 - Renergen Limited (ASX:RLT) CEO Stefano Marani reveals the company's discovery of a 12% helium concentration reserve at the Virginia Gas Project in South Africa.
18 Dec 2019 - Oventus Medical Limited (ASX:OVN) Managing Director and CEO, Dr Chris Hart talks about the company's North American sales process via its lab in lab model and how this improves patient outcomes.
18 Dec 2019 - Prospect Resources Limited (ASX:PSC) Managing Director, Sam Hosack, provides an update on the company's Arcadia lithium project in Zimbabwe, including advanced negotiations with a number of African and international banks on funding.
17 Dec 2019 - Wisr Limited (ASX:WZR) CEO, Anthony Nantes talks about the company's partnership with NAB to provide an initial $50m in funding to support its personal loan book and diversify its funding partners.
17 Dec 2019 - Integrated Payment Technologies (ASX:IP1) CEO, Dean Martin discusses the company's payments solutions ClickSuper and PayVu, industry tailwinds, new features and platform integration.
17 Dec 2019 - Aus Tin Mining Limited (ASX:ANW) CEO, Peter Williams discusses the funding package and resumption plan for the Granville Tin Project and plans for Granville to be a foundation asset in a proposed IPO.
16 Dec 2019 - Sienna Cancer Diagnostics Limited (ASX:SDX) Managing Director and CEO Carl Stubbings talks about the company's capital raising and co-development of tests using its SIEN-NET liquid biopsies platform technology.
16 Dec 2019 - Openpay Group Limited (ASX:OPY) CEO & MD, Michael Eidel talks about the company's business model, the size of the opportunity and how it differentiates itself from other buy now pay later (BNPL) providers.
16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.
